22 November 2024
Starpharma secures FDA agreement on BV treatment Phase 3
Melbourne, Australia; 10 October 2011: Starpharma Holdings Limited (ASX: SPL; OCTQX: SPHRY) today announced that the Phase 3 clinical trial program for the VivaGel® bacterial vaginosis (BV) treatment program has been agreed with the US Food and Drug Administration (FDA) following recent positive trial results and subsequent End of Phase 2 (EOP2) Meeting.
With very positive Phase 2 results for VivaGel® in the treatment of BV (announced May 2011), Starpharma recently presented to the FDA the proposed design of Phase 3 studies and associated aspects of the development program to support a New Drug Application (NDA) for VivaGel® for the treatment of BV.
Following these EOP2 meeting discussions, Starpharma and the FDA are now in agreement on Phase 3 clinical trial design, including definition of primary and secondary endpoints, patient numbers and other design parameters. The company now plans to submit its Phase 3 protocols as soon as possible and it is anticipated that the trials will commence in early 2012 with completion expected before year end. Following the completion of Phase 3 trials the company plans to partner the product.
Consistent with Starpharma’s original plans for the BV treatment program, these two Phase 3 studies will be conducted in parallel, each with approximately 220 participants enrolled. In these Phase 3 trials, as for the recently completed successful Phase 2 study, the primary endpoint will be Clinical Cure, as assessed by resolution of symptoms and other standard clinical criteria, and the comparator will be placebo gel.
“We are very pleased that the FDA agreed with our proposed clinical program in this important, final phase of the development of VivaGel® as a treatment for bacterial vaginosis and particularly that the design is so similar to our successful Phase 2 trial. We look forward to advancing the program as rapidly as possible, and to executing a commercial licence following its completion,” said Starpharma Chief Executive Officer, Dr Jackie Fairley.
“BV is the most common vaginal infection in the world, and affects an estimated one-third of the adult female population in the US. The global market for topical BV treatments alone is estimated at approximately US$350M and we and others believe VivaGel® has the potential to be a very important product in the management of this serious and unpleasant condition.”
In May, Starpharma announced that VivaGel® had met the primary endpoint of its Phase 2 study, demonstrating significant efficacy for treatment of BV. The study showed that treatment with 1% VivaGel® once daily for seven days, resulted in 74% of patients achieving Clinical Cure of BV 2 to 5 days after completion of therapy compared with just 22% in the placebo group (P=0.0002). In addition, patient acceptability of the product was very high with 83% of patients using 1% VivaGel® being extremely satisfied, very satisfied or satisfied with the product when taking all aspects of the treatment into account.
|
Bacterial Vaginosis is the most common vaginal infection worldwide and is particularly prevalent in the US. Similar to imbalances between “good” and “bad” bacteria in the gut, an imbalance in the vaginal microbiota between good bacteria - which help maintain a normal healthy vagina - and harmful bacteria, leads to BV with symptoms including vaginal irritation, discharge and odour that are unpleasant and disrupt and interfere with a woman’s relationships and general quality of life. The condition also has more serious consequences, being implicated in pelvic inflammatory disease, infertility and an increased risk of pre-term birth. BV also significantly increases the risk of some sexually transmitted infections, including HIV. |
Download ASX Announcement: Starpharma secures FDA agreement on BV treatment Phase 3 (pdf file, 150kb)